Eton Pharmaceuticals Inc. Common Stock (ETON)
Stock · NASDAQ · Health Care
$50.31as of 10/16/2026
Price chart
Active signals
ETON Signal Track Record
How signals performed across all stocks →What ETON's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | +0.2% | 51% | September 18, 2026 |
| Bollinger Band Breakout | 28 | +10.6% | 64% | August 14, 2026 |
| Bollinger Band Breakdown | 14 | +0.8% | 64% | September 30, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +1.9% | 69% | March 6, 2026 |
| Any 20-session window (baseline) | +3.9% | 57% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ETON
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate syn…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 44
- Website
- etonpharma.com/
Fundamentals
- 1-day range
- $51.05$59.66
- Market cap
- $1.26B
- P/E (trailing)
- 133.39
- P/E (forward)
- 20.13
- EPS (trailing)
- $0.39
- Dividend yield
- —
- Beta
- 0.88
- Avg. volume
- 561.7K
How Eton Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Eton Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
- XERSXeris Biopharma Holdings Inc. Common Stock$10.31▲ 2.38%Market cap $1.27BP/E —$5.25$11.33
- MNKDMannKind Corporation Common Stock$3.04▼ 4.70%Market cap $1.24BP/E —$2.23$6.51
- AKTSAktis Oncology Inc. Common stock$15.06▼ 5.93%Market cap $1.30BP/E —$14.72$34.19
- ARDXArdelyx Inc. Common Stock$3.09▼ 5.50%Market cap $1.20BP/E —$3.06$8.4
- MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$9.55▼ 6.92%Market cap $1.33BP/E —$8.8$23.29
- SDGRSchrodinger Inc. Common Stock$22.6▼ 11.30%Market cap $1.33BP/E —$10.95$33.78
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
| XERS Xeris Biopharma Holdings Inc. Common Stock | $1.27B | — | $10.31 | ▲ 2.38% | $5.25$11.33 |
| MNKD MannKind Corporation Common Stock | $1.24B | — | $3.04 | ▼ 4.70% | $2.23$6.51 |
| AKTS Aktis Oncology Inc. Common stock | $1.30B | — | $15.06 | ▼ 5.93% | $14.72$34.19 |
| ARDX Ardelyx Inc. Common Stock | $1.20B | — | $3.09 | ▼ 5.50% | $3.06$8.4 |
| MLTX MoonLake Immunotherapeutics Class A Ordinary Shares | $1.33B | — | $9.55 | ▼ 6.92% | $8.8$23.29 |
| SDGR Schrodinger Inc. Common Stock | $1.33B | — | $22.6 | ▼ 11.30% | $10.95$33.78 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- MAIER PAUL V · August 28, 2026 · Option Exercise12.5K @ $7.31
- MAIER PAUL V · August 28, 2026 · Option Exercise50.0K @ $3.78
- MAIER PAUL V · August 28, 2026 · Sale128 @ $61.77
- MAIER PAUL V · August 28, 2026 · Sale13.5K @ $60.21
- MAIER PAUL V · August 28, 2026 · Sale36.4K @ $58.64
- Krempa David · August 24, 2026 · Option Exercise25.0K @ $7.31
- Krempa David · August 24, 2026 · Sale25.0K @ $65.07
- Matthews Judith M. · July 31, 2026 · Grant32.2K
- Erdogan-Trinkaus Ipek · July 31, 2026 · Grant80.0K
- Krempa David · July 31, 2026 · Grant129.0K
- Adams Jennifer McKie · July 31, 2026 · Grant10.0K
- BRYNJELSEN SEAN · July 31, 2026 · Grant129.0K
- MAIER PAUL V · July 31, 2026 · Grant10.0K
- Norbert G. Riedel · July 31, 2026 · Grant10.0K
- Charles J. Casamento · July 31, 2026 · Grant10.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 17.52M
- Total value held
- $421.69M
- Institutional holders
- 112
- Unknown2.86M
- Unknown2.17M
- Unknown1.72M
- Unknown1.18M
- Unknown994.1K
- Unknown577.7K
- Unknown530.2K
- Unknown492.1K
- Unknown478.0K
- Unknown467.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Eton Secures U.S. License for LIBERVANT Buccal Film
Eton Pharmaceuticals has signed an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT, a buccal film designed to treat seizure clusters in epilepsy patients. The partnership will bring the product to market in April 2027, expanding Eton’s epilepsy portfolio. The deal positions Eton to capture a niche therapeutic area and could support future revenue growth.
Eton Secures U.S. License for LIBERVANT Buccal Film. Eton Pharmaceuticals has signed an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT, a buccal film designed to treat seizure clusters in epilepsy patients. The partnership will bring the product to market in April 2027, expanding Eton’s epilepsy portfolio. The deal positions Eton to capture a niche therapeutic area and could support future revenue growth.